The PSC clinic nurse’s communication challenge
Primary sclerosing cholangitis generates clinical communication failures that share a structural pattern with other rare hepatobiliary diseases but have their own distinctive character: it is a condition in which almost every major clinical decision — how it was diagnosed, what medications are not recommended, why surveillance is performed — runs counter to the reasonable inferences a patient would draw from general knowledge about liver disease. A patient whose doctor has described her condition as a “liver disease” cannot understand why the definitive diagnostic test is an MRI of the bile ducts. A patient who knows someone with primary biliary cholangitis — a bile duct disease that sounds identical — taking ursodeoxycholic acid with apparent benefit cannot understand why her hepatologist specifically advises against that medication for her. And a patient whose inflammatory bowel disease is in complete remission, who feels well, and who has no family history of colon cancer cannot understand why her gastroenterologist insists on an annual colonoscopy that begins immediately after the PSC diagnosis, years earlier than the surveillance timeline for IBD alone.
Each of these communication failures is driven by the same underlying reality: PSC operates by mechanisms that are specific enough to override the general rules patients apply from their knowledge of liver disease, IBD, and cancer screening. The nurse who can translate those mechanisms into accessible, mechanistically accurate Spanish is not filling in a courtesy gap — she is providing the only explanation that will produce genuine understanding and adherence in a disease where the instructions, without context, appear contradictory.
Three conversations that recur with Spanish-speaking patients across the PSC clinic setting:
Scenario 1: María Guadalupe Salazar-Pérez — 38, dental hygienist from Houston, Texas
María Guadalupe Salazar-Pérez had been a dental hygienist in Houston’s Memorial neighborhood for fourteen years. She was the person in the clinic who paid attention to details, who caught the retraction others missed, who double-checked her instruments. She brought the same meticulous attention to her own health. She had been followed for ulcerative colitis for six years — diagnosed after she developed bloody diarrhea that she initially attributed to a GI virus and then to stress, and finally brought to a gastroenterologist who did a colonoscopy. She had managed her UC with mesalamine, had two mild flares in six years, and had been in clinical remission for the past two years.
At her annual GI follow-up, her gastroenterologist had run routine labs that included a liver panel, and the alkaline phosphatase had come back elevated at 310 U/L — more than three times the upper limit of normal. Her AST and ALT were mildly elevated. She had no symptoms she could attribute to her liver: no jaundice, no itching, no pain in the right upper quadrant. The gastroenterologist had referred her to hepatology for evaluation, and the hepatologist had ordered an MRCP.
The MRCP showed multifocal stricturing and upstream dilatation of the intrahepatic and extrahepatic bile ducts — the characteristic beaded appearance — and the hepatologist had called her with the diagnosis: primary sclerosing cholangitis. He had explained that it was a bile duct disease that was likely connected to her ulcerative colitis, that there was no medication proven to change its course, and that he would see her every six months for monitoring.
Her husband Roberto had come with her to the first hepatology visit. Roberto was an electrical engineer — systematic, mechanically minded — and he had not been able to reconcile what he had heard. At the PSC clinic nurse’s intake session, he was the one who asked first.
“El doctor dice que es una enfermedad del hígado,” he said. “Pero la prueba que la diagnosticó fue una resonancia magnética de los conductos. Si es una enfermedad del hígado, ¿por qué no se diagnosticó con una biopsia del hígado? ¿Y qué tiene que ver con su colitis? No estoy entendiendo cómo se relaciona todo esto.” (The doctor says it is a liver disease. But the test that diagnosed it was an MRI of the ducts. If it is a liver disease, why wasn’t it diagnosed with a liver biopsy? And what does it have to do with her colitis? I am not understanding how all of this is related.)
PSC clinic nurse Elena Vargas-Castillo recognized the question immediately as the one that would determine whether Roberto became an ally in María’s care or a source of ongoing confusion. Getting the architecture right — what PSC actually is, where it lives in the body, what it does — was the foundation everything else would rest on.
“La confusión sobre la prueba tiene sentido,” Elena said, “porque el PSC se llama a veces ‘enfermedad del hígado’ y a veces ‘enfermedad biliar’ y los dos términos son correctos pero el segundo describe mejor dónde está el problema original. Quiero explicarles qué es el PSC realmente, porque eso también explica por qué la resonancia y por qué la colitis están relacionados.” (The confusion about the test makes sense, because PSC is sometimes called a ‘liver disease’ and sometimes a ‘biliary disease’ and both terms are correct but the second describes better where the original problem is. I want to explain what PSC actually is, because that also explains why the MRI and why the colitis are connected.)
She started with the anatomy. The liver, she explained, has two main jobs: it makes bile — a fluid that helps digest fats — and it metabolizes substances the body needs to process. The bile that the liver makes flows out of the liver through a system of tubes called the bile ducts. The smallest bile ducts are inside the liver itself. They connect to progressively larger ducts that eventually form two main ducts exiting the liver, which join into a single common bile duct that empties into the small intestine at the ampulla of Vater.
“En el PSC, el sistema inmune ataca esos conductos biliares,” Elena said. “Produce inflamación en la pared de los conductos, y esa inflamación produce cicatrización — la pared del conducto se engrosa y se estrecha. En muchos puntos a lo largo de los conductos biliares — tanto los que están dentro del hígado como los que están fuera — se forman esas estrecheces, que se llaman estenosis. Entre una estenosis y la siguiente, el conducto se dilata porque la bilis no puede pasar fácilmente. Eso produce la imagen que se vio en la resonancia: un conducto que en algunos puntos es muy estrecho y en otros es muy ancho — la imagen que los médicos llaman ‘en rosario’ o ‘arrosariado’.” (In PSC, the immune system attacks those bile ducts. It produces inflammation in the wall of the ducts, and that inflammation produces scarring — the duct wall thickens and narrows. At many points along the bile ducts — both those inside the liver and those outside — those strictures form. Between one stricture and the next, the duct dilates because the bile cannot pass easily. That produces the image seen on the MRI: a duct that at some points is very narrow and at others is very wide — the image doctors call ‘beaded’ or ‘string of beads.’)
Roberto was following closely. “Y el hígado — ¿cómo se afecta?” (And the liver — how is it affected?)
“El hígado se daña porque la bilis no puede salir bien,” Elena said. “Cuando los conductos están estrechados, la bilis se acumula dentro del hígado. Los ácidos biliares son químicamente activos — son detergentes que disuelven las grasas en el intestino. Cuando se acumulan dentro del hígado, dañan las células del hígado. Con el tiempo, ese daño produce cicatrización en el hígado — fibrosis — y si avanza, cirrosis. Pero ese daño en el hígado es la consecuencia de los conductos estrechados. El problema original está en los conductos, no en el hígado.” (The liver is damaged because bile cannot exit well. When the ducts are narrowed, bile accumulates inside the liver. Bile acids are chemically active — they are detergents that dissolve fats in the intestine. When they accumulate inside the liver, they damage the liver cells. Over time, that damage produces scarring in the liver — fibrosis — and if it advances, cirrhosis. But that liver damage is the consequence of the narrowed ducts. The original problem is in the ducts, not in the liver.)
María had been listening with her arms crossed — the posture of someone trying to hold everything together. “¿Y la biopsia del hígado?” (And the liver biopsy?)
“La biopsia del hígado puede mostrar los efectos del PSC en el tejido del hígado — la fibrosis alrededor de los conductos pequeños, el daño en las células del hígado,” Elena said. “Pero no puede ver las estrecheces en los conductos más grandes, que son la señal diagnóstica del PSC. Es como tratar de diagnosticar un problema en una tubería mirando las grietas en la pared del cuarto en lugar de ver la tubería directamente. La grieta dice que hay un problema, pero no dice dónde está la oclusión. La resonancia de los conductos — la MRCP — ve la tubería. Por eso es la prueba que diagnóstica el PSC.” (The liver biopsy can show the effects of PSC on the liver tissue — the fibrosis around the small ducts, the damage to the liver cells. But it cannot see the strictures in the larger ducts, which are the diagnostic signal of PSC. It is like trying to diagnose a problem in a pipe by looking at cracks in the room wall instead of seeing the pipe directly. The crack says there is a problem, but does not say where the blockage is. The duct MRI — the MRCP — sees the pipe. That is why it is the test that diagnoses PSC.)
Roberto looked at María. “Eso tiene sentido,” he said. “¿Y la colitis?” (That makes sense. And the colitis?)
Elena explained the PSC-IBD connection. The immune system that attacks the bile ducts in PSC and the immune dysregulation that produces the IBD are not independent processes occurring by coincidence in the same patient. There is a shared immune pathology: the same immune cells, particularly activated T lymphocytes and natural killer T cells, are involved in both the biliary inflammation of PSC and the intestinal inflammation of IBD. The evidence is the remarkably high co-occurrence: approximately 70 to 80 percent of patients with large-duct PSC also have IBD, most commonly ulcerative colitis. The directionality is bi-directional: PSC patients with UC often have a distinctive UC phenotype (pancolitis, backwash ileitis, relative rectal sparing) that differs from UC in patients without PSC. In the other direction, having UC increases the risk of developing PSC, and having PSC increases the severity of colorectal neoplasia risk from the UC.
“La conexión entre el PSC y la colitis no es casualidad,” Elena said. “Ambas enfermedades involucran el mismo tipo de desregulación inmune. En algunos pacientes, esa desregulación se expresa principalmente en los conductos biliares. En otros, principalmente en el intestino. En una proporción importante de pacientes, en los dos. Por eso el 70 u 80 por ciento de los pacientes con PSC tiene colitis — no porque una causó la otra, sino porque tienen el mismo sustrato inmune.” (The connection between PSC and colitis is not coincidence. Both diseases involve the same type of immune dysregulation. In some patients, that dysregulation expresses primarily in the bile ducts. In others, primarily in the intestine. In a significant proportion of patients, in both. That is why 70 or 80 percent of patients with PSC have colitis — not because one caused the other, but because they share the same immune substrate.)
María uncrossed her arms. “O sea que la colitis y el PSC son dos manifestaciones del mismo problema inmune.” (So the colitis and PSC are two manifestations of the same immune problem.)
“Eso es exactamente la manera de entenderlo.” (That is exactly the way to understand it.)
Scenario 2: Daniela Cruz-Vásquez — 45, school administrator from San Antonio, Texas
Daniela Cruz-Vásquez had been the assistant principal of a middle school in San Antonio’s Northside district for nine years. She ran a school of 800 students with the combination of warmth and precision that made her effective with parents, teachers, and twelve-year-olds in equal measure. She had been diagnosed with large-duct PSC six months earlier after a workup for persistently elevated liver enzymes that had been noted on an insurance physical two years before and then dismissed as “probably a fatty liver,” re-evaluated after she pushed her primary care doctor to investigate further. The MRCP showed the characteristic multifocal stricturing. There was no IBD on colonoscopy.
At her second hepatology visit, she had a question she had been sitting on since the diagnosis. Her friend Elena, who attended the same church, had been diagnosed with primary biliary cholangitis three years earlier and was doing well on ursodeoxycholic acid. Elena had encouraged Daniela to ask her hepatologist about UDCA — “it’s for the bile ducts, just like your thing,” Elena had said — and Daniela had been surprised and slightly confused when her hepatologist said UDCA was not recommended for PSC.
“Mi amiga Elena tiene PBC y toma ursodeoxicólico y sus enzimas han mejorado mucho,” she said at the intake session with PSC clinic nurse Marisol Fuentes-Guerrero. “Ella me dijo que probablemente me ayudaría a mí también porque los dos son enfermedades de los conductos biliares. El doctor me dijo que no está recomendado para el PSC. ¿Por qué funciona para ella y no está indicado para mí?” (My friend Elena has PBC and takes ursodeoxycholic acid and her enzymes have improved a lot. She told me it would probably help me too because both are bile duct diseases. The doctor told me it is not recommended for PSC. Why does it work for her and is not indicated for me?)
Marisol recognized this as a question that required both a medical answer and a reframe of what “works” means in clinical medicine, because the story of UDCA in PSC is specifically a story of a medication that can make certain numbers look better while making outcomes worse.
“La pregunta de su amiga tiene una lógica perfecta,” Marisol said. “Pero la respuesta requiere explicar algo importante sobre cómo funciona la investigación médica: la diferencia entre mejorar los números en un análisis de sangre y mejorar lo que le pasa al paciente. Con la ursodeoxicólico en el PSC, esas dos cosas apuntan en direcciones opuestas.” (Your friend’s question has perfect logic. But the answer requires explaining something important about how medical research works: the difference between improving the numbers in a blood test and improving what happens to the patient. With ursodeoxycholic acid in PSC, those two things point in opposite directions.)
She explained how UDCA works in PBC first, because Daniela needed to understand why it makes sense there before understanding why PSC is different. In PBC, the bile duct damage is driven by hydrophobic primary bile acids accumulating in the liver when the small intrahepatic ducts are progressively destroyed by the autoimmune attack. Ursodeoxycholic acid — a naturally occurring hydrophilic bile acid — is incorporated into the bile acid pool and displaces the cytotoxic hydrophobic bile acids, reducing hepatocyte and cholangiocyte membrane disruption. Multiple randomized controlled trials and large cohort studies have shown that UDCA at standard doses in PBC improves biochemical markers and — critically — improves transplant-free survival in patients who achieve adequate biochemical response. The biomarker improvement and the survival improvement go in the same direction.
“En el PBC, el medicamento mejora los análisis y mejora la supervivencia. Por eso está indicado,” Marisol said. “En el PSC, la historia es diferente. Hay ensayos clínicos que probaron la ursodeoxicólico en el PSC. En esos estudios, la ursodeoxicólico sí mejoraba la fosfatasa alcalina — los análisis de sangre mejoraban. Pero en el estudio más grande, que probó dosis altas del medicamento, los resultados reales — trasplantes de hígado, muertes, complicaciones graves — empeoraron en el grupo que tomaba el medicamento comparado con el grupo que tomaba el placebo.” (In PBC, the medication improves the tests and improves survival. That is why it is indicated. In PSC, the story is different. There are clinical trials that tested ursodeoxycholic acid in PSC. In those studies, ursodeoxycholic acid did improve the alkaline phosphatase — the blood tests improved. But in the largest study, which tested high doses of the medication, the real outcomes — liver transplants, deaths, serious complications — worsened in the group taking the medication compared to the group taking placebo.)
Daniela’s expression shifted — she was listening the way she listened when a teacher was explaining something counterintuitive. “¿El medicamento mejoró los análisis pero empeoró los resultados reales?” (The medication improved the tests but worsened the real outcomes?)
“Sí. Ese es exactamente el punto. Y es importante, porque en medicina hay una tentación a decir ‘si el análisis mejora, el paciente está mejor.’ A veces eso es verdad. A veces no. La fosfatasa alcalina alta en el PSC es una consecuencia del daño biliar, pero bajarla con un medicamento no significa necesariamente que el daño biliar está siendo corregido. Puede significar que el medicamento está cambiando cómo el hígado procesa las enzimas sin cambiar lo que le está pasando a los conductos.” (Yes. That is exactly the point. And it is important, because in medicine there is a temptation to say ‘if the test improves, the patient is better.’ Sometimes that is true. Sometimes it is not. High alkaline phosphatase in PSC is a consequence of biliary damage, but lowering it with a medication does not necessarily mean the biliary damage is being corrected. It can mean the medication is changing how the liver processes enzymes without changing what is happening to the ducts.)
Marisol described the HIGH-UDCA trial in accessible terms. The study randomized PSC patients to high-dose ursodeoxycholic acid (17 to 23 mg per kilogram per day — substantially higher than the doses used in PBC) or placebo and followed them over several years. The trial was stopped early because an interim analysis showed that the patients in the UDCA group were experiencing significantly more serious adverse events than the placebo group: higher rates of the composite endpoint that included death, liver transplantation, or development of high-grade dysplasia or cholangiocarcinoma. The alkaline phosphatase in the UDCA group was lower — the biomarker improved. But the patients were doing worse.
“El estudio se paró antes de tiempo porque los investigadores vieron que estaba haciendo daño,” Marisol said. “Ese tipo de decisión — parar un estudio por seguridad — es rara y se toma en serio. No fue un estudio que simplemente no mostró beneficio. Fue un estudio que mostró daño. Por eso las guías médicas internacionales no recomiendan la ursodeoxicólico para el PSC.” (The study was stopped early because the researchers saw it was causing harm. That type of decision — stopping a study for safety — is rare and is taken seriously. It was not a study that simply showed no benefit. It was a study that showed harm. That is why the international medical guidelines do not recommend ursodeoxycholic acid for PSC.)
Daniela absorbed this. “¿Y entonces qué se puede hacer? Si no hay medicamento que funcione para el PSC, ¿qué estamos haciendo en estas visitas?” (And then what can be done? If there is no medication that works for PSC, what are we doing in these visits?)
Marisol had expected this follow-up. “Las visitas tienen dos propósitos,” she said. “El primero es detectar y tratar las complicaciones del PSC. Las estenosis en los conductos biliares pueden empeorar y producir ictericia o colangitis — una infección biliar — y eso se puede tratar con un procedimiento endoscópico que dilata la estenosis. El segundo propósito es la vigilancia. El PSC aumenta el riesgo de un cáncer en los conductos biliares que se llama colangiocarcinoma. Ese cáncer es difícil de detectar y sus síntomas son similares a los de la colangitis o el PSC que empeora. El seguimiento regular con ultrasonido y análisis específicos permite detectarlo temprano, cuando puede tratarse.” (The visits have two purposes. The first is to detect and treat the complications of PSC. Strictures in the bile ducts can worsen and produce jaundice or cholangitis — a biliary infection — and that can be treated with an endoscopic procedure that dilates the stricture. The second purpose is surveillance. PSC increases the risk of a cancer in the bile ducts called cholangiocarcinoma. That cancer is difficult to detect and its symptoms are similar to those of cholangitis or worsening PSC. Regular follow-up with ultrasound and specific tests allows it to be detected early, when it can be treated.)
She also mentioned that clinical trials of new therapies for PSC — FXR agonists, anti-fibrotics, targeted immune modulators — were actively ongoing, and that if Daniela was interested in trial participation, the hepatology clinic could assess eligibility. “Hay investigación activa. La ausencia de tratamiento aprobado hoy no significa que no habrá tratamiento en los próximos años.” (There is active research. The absence of approved treatment today does not mean there will be no treatment in the coming years.)
Daniela nodded. “Voy a decirle a Elena que el PSC y el PBC son más diferentes de lo que parece.” (I am going to tell Elena that PSC and PBC are more different than they appear.)
Scenario 3: Carmen Estrada-Moreno — 52, retail store manager from Phoenix, Arizona
Carmen Estrada-Moreno had managed a large clothing retailer’s Scottsdale location for eleven years. She was the person who knew all 45 of her employees by name, who stayed late when the floor was understaffed, who had built a team with low turnover in a notoriously high-turnover industry. She had been living with ulcerative colitis for seventeen years — diagnosed at 35 after a prolonged episode of bloody diarrhea, managed over the years with mesalamine and one course of steroids, and currently in clinical and endoscopic remission on vedolizumab that her gastroenterologist had started three years ago.
Six months ago, her gastroenterologist had found an elevated alkaline phosphatase on routine labs and referred her to a hepatologist, who had diagnosed PSC by MRCP. The PSC affected the larger extrahepatic bile ducts and some smaller intrahepatic ducts. She had no dominant stricture requiring intervention. The hepatologist had set her up with routine follow-up every six months and had referred her back to her gastroenterologist with a note about PSC-IBD and the colonoscopy surveillance recommendation.
Her gastroenterologist had told her at her next visit that in the setting of PSC, the colonoscopy surveillance schedule would change: instead of colonoscopy every two to three years based on the seventeen-year UC duration, she would now need annual colonoscopy. The gastroenterologist had explained it briefly — “PSC significantly elevates colorectal cancer risk, so we need to watch more closely” — and Carmen had nodded and scheduled the colonoscopy. But she had been thinking about it for two months, and she could not make it fit with what she knew about her situation.
At the PSC clinic nurse intake session with Ana Martínez-Reyes, Carmen asked about it before the nurse had even pulled up her chart.
“Me dijeron que necesito una colonoscopía cada año por el PSC,” she said. “Pero mi colitis lleva tres años en remisión completa. No tengo síntomas intestinales. Y no tengo historia familiar de cáncer de colon. Entiendo que el PSC es serio, pero no estoy entendiendo por qué una enfermedad de los conductos biliares cambia cuándo necesito la colonoscopía. ¿Por qué la remisión de la colitis no cuenta para eso?” (They told me I need a colonoscopy every year because of the PSC. But my colitis has been in complete remission for three years. I have no bowel symptoms. And I have no family history of colon cancer. I understand PSC is serious, but I am not understanding why a bile duct disease changes when I need the colonoscopy. Why doesn’t the remission of the colitis count for that?)
Ana recognized the precision of Carmen’s question. She was not resisting the colonoscopy — she had scheduled it. She was trying to understand the logic, because she was the kind of person who needed to understand the logic of what she was doing. The explanation required separating the mechanism of colorectal cancer risk in PSC-IBD from the mechanism in standard IBD — two overlapping but structurally different risk architectures.
“La remisión de la colitis sí cuenta — para el riesgo de la colitis sola,” Ana said. “Pero el PSC agrega un riesgo de cáncer de colon que es independiente de la actividad de la colitis. Necesito explicarle cómo funciona ese riesgo, porque es genuinamente diferente del riesgo de la colitis sin PSC.” (The remission of the colitis does count — for the risk of colitis alone. But PSC adds a colorectal cancer risk that is independent of colitis activity. I need to explain how that risk works, because it is genuinely different from the risk of colitis without PSC.)
She started with the baseline CRC risk in ulcerative colitis without PSC. The risk is elevated compared to the general population and increases with disease duration, extent of colonic involvement, and degree of chronic mucosal inflammation. After approximately 8 to 10 years of disease, annual or biennial colonoscopy is recommended. The risk correlates with histologic activity: patients in deep histologic remission have lower CRC risk than patients with persistent microscopic inflammation. This is the risk model Carmen had been operating under for seventeen years — and it is accurate for UC without PSC.
“En la colitis con PSC, ese modelo no aplica de la misma manera,” Ana said. “Los estudios de población que han seguido a pacientes con colitis durante años muestran que los pacientes con colitis y PSC tienen un riesgo de cáncer de colon que es cinco a diez veces mayor que los pacientes con colitis sola — sin importar cuánto tiempo llevan con la colitis, sin importar si la colitis está activa o en remisión, y sin importar si hay historia familiar de cáncer de colon. El riesgo está elevado desde el inicio del PSC, no despues de diez años de colitis.” (In colitis with PSC, that model does not apply in the same way. Population studies that have followed patients with colitis over years show that patients with colitis and PSC have a colorectal cancer risk that is five to ten times higher than patients with colitis alone — regardless of how long they have had colitis, regardless of whether the colitis is active or in remission, and regardless of whether there is a family history of colorectal cancer. The risk is elevated from the start of PSC, not after ten years of colitis.)
Carmen’s eyes narrowed. “¿Cinco a diez veces más?” (Five to ten times higher?)
“Sí. Y lo que hace eso clínicamente importante es la segunda parte: en la colitis con PSC, los cambios premaligrnos en el colon — la displasia — aparecen sin síntomas. En la colitis sola, los pacientes con displasia frecuentemente tienen síntomas de inflamación activa que llevan al endoscopista a biopsiar más agresivamente. En la colitis con PSC, la displasia puede aparecer en mucosa que se ve endoscópicamente normal, en un colon que está en remisión completa, en una persona que no tiene ningún síntoma. Por eso la remisión de la colitis no reduce el riesgo de la manera en que reduciría si no tuviera PSC.” (Yes. And what makes that clinically important is the second part: in colitis with PSC, the precancerous changes in the colon — dysplasia — appear without symptoms. In colitis alone, patients with dysplasia frequently have symptoms of active inflammation that lead the endoscopist to biopsy more aggressively. In colitis with PSC, dysplasia can appear in mucosa that looks endoscopically normal, in a colon that is in complete remission, in a person who has no symptoms at all. That is why the remission of colitis does not reduce the risk in the way it would if you did not have PSC.)
Carmen sat with this for a moment. “¿Por qué el PSC aumenta tanto el riesgo en el colon? La enfermedad está en los conductos biliares.” (Why does PSC increase the risk so much in the colon? The disease is in the bile ducts.)
Ana explained the hypothesized mechanisms. When bile flow from the liver is impaired — as in PSC — the composition of bile that reaches the intestine changes. The normal bile acid pool contains a mix of primary bile acids (cholic acid, chenodeoxycholic acid) secreted by the liver and secondary bile acids (deoxycholic acid, lithocholic acid) formed by intestinal bacteria from the primary bile acids. In PSC, with impaired biliary secretion and altered intrahepatic bile acid chemistry, the bile acids that reach the colon are present in abnormal quantities and compositions. In particular, secondary bile acids like deoxycholic acid and lithocholic acid — formed from primary bile acids by colonic bacterial metabolism — have direct carcinogenic effects on colonic epithelium: they cause DNA damage through oxidative stress, alter the balance of colonocyte proliferation and apoptosis in a pro-tumor direction, and promote a pro-inflammatory colonic microenvironment. Patients with PSC and IBD also have distinct gut microbiome compositions compared to IBD alone, with microbiome patterns that may further amplify the carcinogenic potential of the altered bile acid pool reaching the colon.
“Los ácidos biliares que llegan al colon en cantidades anormales actúan como carcinógenos en las células del colon,” Ana said. “Dañan el ADN de esas células de maneras que eventualmente producen displasia y cáncer. Y como eso ocurre independientemente de si la colitis está activa, la remisión de la colitis reduce la inflamación del colon pero no reduce la exposición al efecto de esos ácidos biliares anormales.” (The bile acids that reach the colon in abnormal amounts act as carcinogens on the colon cells. They damage the DNA of those cells in ways that eventually produce dysplasia and cancer. And since that occurs independently of whether the colitis is active, the remission of the colitis reduces colon inflammation but does not reduce the exposure to the effect of those abnormal bile acids.)
Carmen was nodding slowly — the nod of someone rearranging mental categories. “O sea que la colonoscopía anual es para vigilar un riesgo que existe aunque yo no sienta nada y aunque la colitis esté bien controlada.” (So the annual colonoscopy is to monitor a risk that exists even though I feel nothing and even though the colitis is well controlled.)
“Exactamente. Y la vigilancia anual en el PSC-colitis empieza desde que se diagnostica el PSC — no desde que se cumple el tiempo de la colitis. En el PSC, la exposición a los ácidos biliares anormales comienza desde el inicio de la enfermedad biliar, no después de diez años de colitis.” (Exactly. And annual surveillance in PSC-colitis starts from when PSC is diagnosed — not from when the time limit of colitis is reached. In PSC, the exposure to abnormal bile acids begins from the start of the biliary disease, not after ten years of colitis.)
She also explained that the annual colonoscopy in PSC-IBD used chromoendoscopy — dye-spraying techniques or virtual chromoendoscopy — to improve detection of flat dysplastic lesions that could be missed by standard white-light endoscopy. “La colonoscopía de vigilancia en el PSC no es la misma que la colonoscopía estándar. El endoscopista usa técnicas especiales para ver mejor la mucosa y detectar cambios que son muy sutiles.” (The surveillance colonoscopy in PSC is not the same as a standard colonoscopy. The endoscopist uses special techniques to see the mucosa better and detect changes that are very subtle.)
Carmen scheduled the colonoscopy for the following month. Before she left, she said: “Me alegra haber preguntado. Había decidido hacer lo que me dijeron, pero sin entender por qué. Ahora lo entiendo.” (I am glad I asked. I had decided to do what I was told, but without understanding why. Now I understand.)
Eight practical phrases for PSC clinic nurses
- Explaining why MRCP is the diagnostic test for PSC rather than liver biopsy: “El PSC es principalmente una enfermedad de los conductos biliares — los tubos que llevan la bilis del hígado al intestino. La resonancia magnética de los conductos biliares puede ver las estrecheces en esos conductos que son la señal diagnóstica del PSC. La biopsia del hígado puede mostrar el daño que esas estrecheces producen en el hígado, pero no puede ver los conductos directamente.” (PSC is primarily a disease of the bile ducts — the tubes that carry bile from the liver to the intestine. The MRI of the bile ducts can see the strictures in those ducts that are the diagnostic signal of PSC. The liver biopsy can show the damage that those strictures produce in the liver, but it cannot see the ducts directly.)
- Explaining why UDCA is not recommended for PSC despite working for PBC: “En el PBC, la ursodeoxicólico mejora los análisis y mejora la supervivencia. En el PSC, los estudios clínicos mostraron que mejoraba los análisis pero aumentaba las complicaciones graves. Por eso las guías médicas no la recomiendan para el PSC. El PBC y el PSC tienen similitudes superficiales, pero el medicamento se comporta de manera diferente en las dos enfermedades.” (In PBC, ursodeoxycholic acid improves tests and improves survival. In PSC, clinical studies showed it improved tests but increased serious complications. That is why medical guidelines do not recommend it for PSC. PBC and PSC have superficial similarities, but the medication behaves differently in the two diseases.)
- Explaining annual colonoscopy in PSC-IBD despite IBD remission: “El PSC aumenta el riesgo de cáncer de colon entre cinco y diez veces, independientemente de la actividad de la colitis. Ese riesgo aumentado está presente aunque la colitis esté en remisión completa, porque el PSC cambia la composición de los ácidos biliares que llegan al colon de manera que daña el ADN de las células del colon. Por eso la colonoscopía anual está indicada aunque no haya síntomas intestinales.” (PSC increases colorectal cancer risk five to tenfold, independently of colitis activity. That elevated risk is present even when colitis is in complete remission, because PSC changes the composition of the bile acids that reach the colon in a way that damages colon cell DNA. That is why annual colonoscopy is indicated even when there are no bowel symptoms.)
- Explaining the PSC-IBD connection to patients and families: “El PSC y la enfermedad inflamatoria del intestino están conectados porque comparten el mismo tipo de desregulación del sistema inmune. En la mayoría de los pacientes con PSC, el sistema inmune ataca tanto los conductos biliares como el intestino. Por eso un 70 a 80 por ciento de los pacientes con PSC también tienen colitis o enfermedad de Crohn — no es coincidencia, es la misma enfermedad inmune manifestándose en dos lugares.” (PSC and inflammatory bowel disease are connected because they share the same type of immune system dysregulation. In most PSC patients, the immune system attacks both the bile ducts and the intestine. That is why 70 to 80 percent of patients with PSC also have colitis or Crohn's disease — it is not coincidence, it is the same immune disease manifesting in two places.)
- Explaining cholangiocarcinoma surveillance in PSC: “El PSC aumenta el riesgo de un cáncer en los conductos biliares llamado colangiocarcinoma. Los síntomas del colangiocarcinoma — ictericia, dolor, pérdida de peso — son similares a los síntomas del PSC cuando empeora. Por eso se hace ultrasonido y un análisis de sangre llamado CA 19-9 regularmente, para detectar el cáncer en etapa temprana antes de que produzca síntomas.” (PSC increases the risk of a cancer in the bile ducts called cholangiocarcinoma. The symptoms of cholangiocarcinoma — jaundice, pain, weight loss — are similar to the symptoms of PSC when it worsens. That is why ultrasound and a blood test called CA 19-9 are done regularly, to detect the cancer at an early stage before it produces symptoms.)
- Explaining what PSC clinic follow-up accomplishes without a curative medication: “Aunque no hay un medicamento que cambie el curso del PSC, el seguimiento regular tiene dos propósitos importantes: detectar y tratar las complicaciones de las estenosis biliares — ictericia, colangitis — cuando son tratables con un procedimiento endoscópico, y vigilar el riesgo de colangiocarcinoma y cáncer de colon que el PSC aumenta. El seguimiento no es ‘esperar que pase algo.’ Es detección activa de complicaciones tratables.” (Although there is no medication that changes the course of PSC, regular follow-up has two important purposes: detecting and treating the complications of biliary strictures — jaundice, cholangitis — when they are treatable with an endoscopic procedure, and monitoring the risk of cholangiocarcinoma and colorectal cancer that PSC increases. Follow-up is not ‘waiting for something to happen.’ It is active detection of treatable complications.)
- Explaining dominant stricture and ERCP in PSC: “A veces una de las estrecheces en los conductos biliares se pone mucho más apretada que las demás — eso se llama una estenosis dominante. Cuando eso pasa, la bilis no puede salir bien y puede causar ictericia o infección biliar. Eso se trata con un procedimiento que se llama CPRE — una cámara que va por la boca hasta el intestino, entra al conducto biliar, y lo dilata con un balón o pone un tubo para mantenerlo abierto. No es una cirugía — es un procedimiento endoscópico.” (Sometimes one of the strictures in the bile ducts becomes much tighter than the others — that is called a dominant stricture. When that happens, bile cannot exit well and can cause jaundice or biliary infection. That is treated with a procedure called ERCP — a camera that goes through the mouth to the intestine, enters the bile duct, and dilates it with a balloon or places a tube to keep it open. It is not surgery — it is an endoscopic procedure.)
- Explaining the importance of reporting new jaundice or fever in PSC: “En el PSC, hay dos síntomas nuevos que siempre necesitan evaluación urgente: la piel o los ojos que se ponen amarillos — ictericia — y fiebre con dolor en el lado derecho del abdomen. Esos síntomas pueden significar que una estenosis biliar empeoró o que hay una infección en el conducto biliar — colangitis — que se puede tratar bien si se detecta rápido pero que puede ser peligrosa si se espera demasiado. Si tiene alguno de esos síntomas, llame antes de la próxima visita programada.” (In PSC, there are two new symptoms that always need urgent evaluation: skin or eyes that turn yellow — jaundice — and fever with pain on the right side of the abdomen. Those symptoms can mean that a biliary stricture worsened or that there is an infection in the bile duct — cholangitis — that can be treated well if detected quickly but that can be dangerous if waited too long. If you have either of those symptoms, call before the next scheduled visit.)
FAQs: primary sclerosing cholangitis, Spanish-speaking patients, and PSC nursing communication
How do primary sclerosing cholangitis clinic nurses explain to a Spanish-speaking patient why PSC is diagnosed with MRCP rather than liver biopsy when the doctor has described it as a liver disease?
PSC is primarily a biliary stricturing disease, not a hepatocyte disease. The defining pathology is multifocal fibro-inflammatory narrowing of the intrahepatic and extrahepatic bile ducts, producing the characteristic “beaded” cholangiographic appearance. Liver damage in PSC is secondary: accumulated bile acids from impaired biliary drainage injure hepatocytes and drive fibrosis. MRCP directly visualizes the biliary tree, showing the multifocal stricturing and upstream dilatation that constitutes the diagnostic anatomy of PSC. Liver biopsy can identify periductal fibrosis and secondary parenchymal damage but cannot show the biliary strictures that define the disease and are the target of therapeutic intervention. ERCP shows the same anatomy and allows therapeutic intervention (balloon dilation, stenting of dominant strictures) but is reserved for therapeutic applications due to procedural risk. The Spanish frame: “El PSC es una enfermedad de los conductos biliares. La resonancia ve las estrecheces en los conductos — esa es la imagen que diagnóstica el PSC. La biopsia ve el daño en el hígado que esas estrecheces producen, pero no puede ver los conductos. Por eso la resonancia es la prueba diagnóstica.”
How do PSC clinic nurses explain to a Spanish-speaking patient why ursodeoxycholic acid is not recommended for PSC when it is used for similar bile duct disease in PBC?
The HIGH-UDCA trial — a randomized, placebo-controlled trial of UDCA at 17–23 mg/kg/day in PSC — was stopped early because patients in the UDCA arm had significantly higher rates of the composite endpoint of death, liver transplantation, and development of high-grade dysplasia or cholangiocarcinoma, despite improved alkaline phosphatase. This illustrates a critical evidence principle: biomarker improvement does not equal clinical benefit, and in PSC, UDCA dissociates the two. The mechanism may involve altered secondary bile acid production (increased lithocholic acid) when high-dose UDCA undergoes colonic bacterial metabolism in the setting of PSC-associated IBD. Current EASL, AASLD, and BSG guidelines do not recommend UDCA at any dose for PSC. The Spanish frame: “El medicamento mejoró los análisis pero empeoró los resultados reales en el ensayo clínico. Eso es lo que llevó a las guías médicas a no recomendarlo. El PBC y el PSC no responden al mismo medicamento de la misma manera.”
How do PSC clinic nurses explain to a Spanish-speaking patient with PSC-associated IBD why annual colonoscopy is required when she has no gastrointestinal symptoms and no family history of colorectal cancer?
PSC-IBD carries colorectal cancer incidence rates 5 to 10 times higher than IBD without PSC in population-based cohort studies, and this elevated risk is present regardless of IBD activity, endoscopic remission, disease duration, or family history. The mechanism involves altered bile acid pool reaching the colon: impaired biliary secretion in PSC results in abnormal bile acid composition and quantity at the colonic epithelium, where secondary bile acids (particularly deoxycholic acid and lithocholic acid) cause oxidative DNA damage, alter colonocyte proliferation/apoptosis balance, and promote a pro-tumorigenic microenvironment. Critically, dysplasia in PSC-IBD develops in endoscopically normal-appearing mucosa without symptomatic correlation, making symptom-based surveillance inadequate. EASL, ACG, and BSG guidelines recommend annual chromoendoscopy beginning at PSC diagnosis regardless of IBD duration, IBD activity, or symptom status. The Spanish frame: “El PSC cambia los ácidos biliares que llegan al colon y eso produce riesgo de cáncer de colon independiente de la colitis. La remisión de la colitis reduce la inflamación, pero no reduce esa exposición. Por eso la colonoscopía anual está indicada aunque todo esté bien.”
How do PSC clinic nurses explain the difference between PSC and PBC to Spanish-speaking patients who know someone with the other condition?
PSC and PBC are both cholestatic liver diseases but have distinct pathophysiology, affected patient demographics, biliary anatomy involvement, treatment response, and complication profiles. PBC: autoimmune CD4/CD8 T-lymphocyte attack on PDC-E2 antigen on small intrahepatic bile duct cholangiocytes; 90% female; diagnosed by AMA-M2 serology; responds to UDCA therapy with improved survival; rare cholangiocarcinoma risk; standard IBD-level CRC risk. PSC: fibro-inflammatory stricturing of intrahepatic and extrahepatic bile ducts including larger ducts; 60–70% male; diagnosed by MRCP/ERCP; no proven medical therapy; substantially elevated cholangiocarcinoma risk; dramatically elevated CRC risk from PSC-IBD. Sharing the “cholestatic liver disease” category makes comparisons natural but the treatment response, complication profile, and surveillance requirements are fundamentally different. The Spanish frame: “El PBC y el PSC son enfermedades de los conductos biliares, pero son diferentes en casi todo: quiénes las tienen, cómo se diagnostican, qué medicamentos funcionan, y qué riesgos producen. El hecho de que su amiga esté bien con el medicamento no dice nada sobre lo que va a funcionar para usted.”
What are the key Spanish phrases PSC clinic nurses use when explaining MRCP diagnosis, UDCA contraindication, and colorectal cancer surveillance to Spanish-speaking PSC patients?
PSC clinic nurses encounter four recurring communication moments. When explaining MRCP for PSC diagnosis: “La resonancia de los conductos biliares ve las estrecheces que definen el PSC. La biopsia del hígado no puede ver los conductos directamente. Por eso la resonancia — no la biopsia — es la prueba que diagnóstica el PSC.” When explaining UDCA contraindication: “En el PSC, la ursodeoxicólico mejoró los análisis pero aumentó las complicaciones graves en el ensayo clínico. El PBC y el PSC responden diferente a ese medicamento.” When explaining annual colonoscopy in PSC-IBD: “El PSC aumenta el riesgo de cáncer de colon entre cinco y diez veces, aunque la colitis esté en remisión. La colonoscopía anual vigila ese riesgo que existe aunque no haya síntomas.” When explaining cholangiocarcinoma surveillance: “El PSC aumenta el riesgo de cáncer en los conductos biliares. El ultrasonido y el CA 19-9 periódicos son para detectar ese cáncer temprano, antes de que produzca síntomas, porque sus síntomas son similares a los del PSC avanzado.”